Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

ONCY $0.99 0.1676 +20.44%
ZIOP $3.31 0.2450 +8.01%
INCY $68.94 4.7600 +7.42%
GERN $2.36 0.1500 +6.79%
MDVN $108.09 5.3500 +5.21%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

AGEN $2.90 -0.1900 -6.15%
ARWR $6.36 -0.3665 -5.45%
OMED $20.95 -1.2000 -5.42%
GALE $2.11 -0.1000 -4.52%
ECYT $5.95 -0.2700 -4.34%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | Next > | Last >>

Maine Hospitals See Price Increase For Specialty Cancer Drugs

(Maine Public Broadcasting [Bangor, ME]) Oct 15, 2014 - A new change in the way three of the most commonly used cancer drugs are distributed could cause new headaches for hospitals and their patients.
read article 



Two-Faced Gene: SIRT6 Prevents Some Cancers But Promotes Sun-Induced Skin Cancer

(University of Chicago Medicine) Oct 15, 2014 - A new study published in Cancer Research shows SIRT6 -- a protein known to inhibit the growth of liver and colon cancers -- can promote the development of skin cancers by turning on an enzyme that increases inflammation, proliferation and survival of sun-damaged skin cells.
read press release 



Can Low-T Therapy Promote Prostate Cancer?

(TIME) Oct 15, 2014 - “Low T” therapy is a fast-growing trend for men who want to jack up testosterone—which declines naturally with age but which can also be clinically low in some people—and the testosterone therapy industry is predicted to reach $5 billion by 2017.
read article 



In Some Men, an Increase in PSA After Prostate Cancer Surgery May Not Lead to Metastasis in Their Lifetime

(AACR) Oct 15, 2014 - Some prostate cancer patients whose prostate-specific antigen (PSA) levels increase after a radical prostatectomy may die of causes unrelated to prostate cancer before they are diagnosed with a prostate cancer metastasis, and therefore treating them for recurrence may not be beneficial, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
read press release 



Side Effects of Cancer Prevention Surgery Can Be Helped With a Single-Day Education Program, Study Finds

(Dana-Farber) Oct 14, 2014 - More women are having ovary-removing surgery as a cancer prevention measure, but many are often unaware of sexual or psychological side effects of the procedure.
read press release 



New Test Can Help Doctors Choose Best Treatment For Ovarian Cancer

(Imperial College London [UK]) Oct 16, 2014 - Researchers have devised a new test to help doctors diagnose ovarian tumours and choose the most appropriate treatment.
read article 



Use of Intensive Medical Services For Ovarian Cancer Patients at End of Life Increases Despite Rise in Use of Hospice

(Dana-Farber) Oct 15, 2014 - As more terminaly ill patients choose to spend their final days and weeks in hospice care rather than a hospital, the hope is the use of intensive and costly hospital services would decline. A new study shows that for one group of terminally ill cancer patients, that is not the case.
read press release 



Dendreon's Provenge Too Expensive For NHS Use, Says NICE

(PharmaTimes [UK]) Oct 16, 2014 - Dendreon’s immunotherapy Provenge (sipuleucel-T) is too expensive to be used as a treatment for advanced prostate cancer on the National Health Service in England, cost regulators have ruled.
read article 



T-Cell Therapy Puts Leukemia Patients in Extended Remission

(New York Times) Oct 15, 2014 - An experimental therapy has brought prolonged remissions to a high proportion of patients who were facing death from advanced leukemia after standard treatments had failed, researchers are reporting.
read article 



Novartis Leukemia Treatment Yields High Remission Rate

(Bloomberg) Oct 15, 2014 - A new leukemia immune treatment being developed by Novartis AG led to the disappearance of cancer in 90 percent of patients, a study showed.
read article 



MD Anderson Study First to Compare Treatments, Survival Benefits for Early-Stage Lung Cancer

(MD Anderson) Oct 15, 2014 - Removal of the entire lobe of lung may offer patients with early-stage lung cancer better overall survival when compared with a partial resection, and stereotactic ablative radiotherapy (SABR) may offer the same survival benefit as a lobectomy for some patients, according to a study from The University of Texas MD Anderson Cancer Center.
read press release 



Cost to NHS of Providing Sipuleucel-T Too High to Be Recommended in Draft Guidance

(NICE) Oct 16, 2014 - NICE has issued preliminary draft guidance not recommending sipuleucel-T for prostate cancer in people whose disease has spread, who have few symptoms and when chemotherapy would not yet have been given.
read press release 



U.S. Top Court Hears Teva's Multiple Sclerosis Drug Patent Fight

(Reuters) Oct 15, 2014 - The U.S. Supreme Court on Wednesday is set to wade into Teva Pharmaceutical Industries Ltd's fight over patent protections for Copaxone, its top-selling multiple sclerosis drug, in one of the most important business cases of the justices' new term.
read article 



U.S. Inversion Rules Cloud AbbVie-Shire Deal

(USA Today) Oct 15, 2014 - Faced with tougher Treasury rules on corporate mergers that are aimed at cutting U.S. tax bills, biopharmaceutical company AbbVie is reconsidering a nearly $55 billion deal with Ireland's Shire Pharmaceuticals.
read article 



Stock Weakness in Seattle Genetics, Gilead Sciences Belies Fundamental Strengths

(TheStreet) Oct 15, 2014 - There's a robust debate among investors around the ability of Seattle Genetics to move up Adcetris into the front-line treatment setting for Hodgkin's lymphoma.
read article 



November 6, 2014: Oncologic Drugs Advisory Committee Meeting Announcement (Updated Information)

(FDA.gov) Oct 14, 2014 - Agenda: During the morning session, the committee will discuss New Drug Application (NDA) 205353, panobinostat capsules, application submitted by Novartis Pharmaceuticals Corporation.
read article 



Embryonic Stem Cells Restore Vision In Preliminary Human Test

(NPR/Shots blog) Oct 14, 2014 - Scientists are reporting the first strong evidence that human embryonic stem cells may be helping patients. The cells appear to have improved the vision in more than half of the 18 patients who had become legally blind because of two progressive, currently incurable eye diseases.
read article 



Navidea Hires Rick Gonzalez as CEO from Spectrum Pharmaceuticals

(Columbus Business First) Oct 15, 2014 - Navidea Biopharmaceuticals Inc. has appointed pharmaceutical executive Rick Gonzalez as CEO, citing his expertise in boosting sales of new drugs and tying part of his compensation to how quickly its struggling stock rises.
read article 



Investigators in The US Oncology Network Bring Advance Care Planning and Molecular Testing to the 2014 ASCO Quality Care Symposium

(McKesson) Oct 14, 2014 - Two abstracts submitted by clinicians and practice representatives affiliated with The US Oncology Network will be presented during the 2014 American Society of Clinical Oncology (ASCO) Quality Care Symposium being held Oct. 17-18 at the Boston Marriott Copley Place in Boston, Mass.
read corporate press release 



ASCO Issues New Template for Survivorship Care Plans

(ASCO) Oct 14, 2014 - The American Society of Clinical Oncology (ASCO) today issued a new template for healthcare professionals to use when providing a survivorship care plan to patients who have completed curative cancer therapy.
read press release 



bioTheranostics Awarded Medicare Coverage for Breast Cancer IndexSM Molecular Test

(DigitalJournal.com) Oct 15, 2014 - bioTheranostics, Inc., a leader in molecular diagnostics for cancer, today announced that its Breast Cancer Index(SM) test has been awarded Medicare coverage.
read article 



Roche Challenges NICE on Kadcyla and Ignoring Pricing Deal

(Pharmaphorum [UK]) Oct 14, 2014 - Yesterday saw Roche mount its appeal against NICE's decision not to recommend Kadcyla, which the NHS body says is too expensive for the benefits it offers patients beyond existing treatments.
read article 



FDA Grants Priority Review Designation for Eisai's Lenvatinib to Treat Advanced Thyroid Cancer

(Pharmaceutical Business Review) Oct 15, 2014 - The US Food and Drug Administration (FDA) has accepted to review Eisai's new drug application (NDA) and has granted Priority Review status for its in-house developed agent lenvatinib mesylate (lenvatinib) to treat progressive radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC).
read article 



Advaxis Provides Clinical Update for Phase 1/2 Trial of ADXS-HPV Immunotherapy Product Candidate in Anal Cancer

(Advaxis) Oct 15, 2014 - Advaxis, Inc. today announced preliminary data from its Phase 1/2 study of ADXS-HPV in human papillomavirus (HPV) associated anal cancer that indicate a "clinical complete response" in all 7 patients who have completed the treatment regimen.
read corporate press release 



Agios Pharmaceuticals Announces Initiation of Four Expansion Cohorts in Phase 1 Study of AG-221

(CNNMoney) Oct 15, 2014 - Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the initiation of four expansion cohorts in its ongoing Phase 1 study of AG-221, a first-in-class, selective, potent IDH2 mutant inhibitor.
read article